BeOne Medicines Reports Record Q2 2026 Revenue of $1.7B, Driven by Brukinsa Growth and Raises Full-Year Guidance
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced Q2 2026 financial results featuring...
Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance
Merck & Co., Inc. (MSD; NYSE: MRK) reported financial results for the second quarter of...
Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA)...
Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%
Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026, with revenues...
CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its...
Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance
Biogen Inc. (NASDAQ: BIIB) released its second-quarter 2026 financial results, reporting revenue of USD 2.736...
Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations
Bayer AG (ETR: BAYN) released its financial results for the second quarter of 2026, reporting...
Takeda Reports Q1 FY2026 Revenue of JPY 1.22 Trillion, Outlines Growth Strategy Centered on Three Key Pipeline Assets
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) released its financial results for the first...
Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership
Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that Oblenio Bio, a NewCo jointly established...
Amgen Reports Q2 2026 Revenue of $10.05B, Driven by 26% Growth in Core Portfolio Despite Denosumab Decline
Amgen (NASDAQ: AMGN) released its financial results for the second quarter of 2026, reporting revenue...
Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), announced that the U.S. Food and Drug...
Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance
Curium Pharma, a private equity-backed radiopharmaceutical company, has agreed to acquire peer Lantheus Holdings (NASDAQ:...
Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients
Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ)‘s New...
Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections
Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced that the Investigational New Drug (IND) application...
Sanofi Secures European Commission Approval for MenQuadfi Pediatric Indication Extension to Infants from Six Weeks of Age
Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has approved an extension of the...
Novo Nordisk Reports Q2 2026 Net Sales of DKK 78.5B, Driven by Strong Semaglutide Performance Despite Portfolio Restructuring
Novo Nordisk (NYSE: NVO) today released its financial results for the second quarter of 2026,...
Alphamab Oncology’s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review
Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name:...
Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year‑Over‑Year
Innovent Biologics (HKG: 1801) today announced its product revenue for the first half of 2026,...
AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance
AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026. Financial Performance...
WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance
WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) released its first-half 2026 (H1’2026) financial results....